Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $60.0833.

A number of equities research analysts have weighed in on the company. Barclays reduced their price objective on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Wedbush reiterated an “outperform” rating and issued a $45.00 price target (down from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Piper Sandler decreased their price target on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, January 16th. Clear Str lowered shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Bank of America lowered their price target on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd.

Insider Buying and Selling

In related news, CEO David Alan Campbell sold 8,072 shares of Janux Therapeutics stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $110,828.56. Following the sale, the chief executive officer directly owned 284,982 shares in the company, valued at $3,912,802.86. The trade was a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas Diraimondo sold 2,505 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $34,393.65. Following the sale, the insider owned 124,425 shares in the company, valued at $1,708,355.25. The trade was a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 22,366 shares of company stock worth $371,245. 8.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System increased its position in Janux Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock worth $858,000 after purchasing an additional 404 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Janux Therapeutics by 8.1% in the second quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock worth $238,000 after acquiring an additional 771 shares in the last quarter. Nuveen LLC boosted its position in Janux Therapeutics by 0.8% during the 4th quarter. Nuveen LLC now owns 96,416 shares of the company’s stock worth $1,331,000 after purchasing an additional 787 shares during the period. Ameritas Investment Partners Inc. increased its holdings in Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares in the last quarter. Finally, Virtus Investment Advisers LLC lifted its stake in shares of Janux Therapeutics by 37.9% during the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $13.70 on Thursday. The company has a fifty day moving average of $13.74 and a two-hundred day moving average of $20.85. The company has a market capitalization of $824.06 million, a PE ratio of -8.15 and a beta of 2.88. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.